Peptides 101: What They Are and How to Think About Them

“Peptide” has become a wellness buzzword, but it is not a product, a brand, or a promise. It is a structural description of a molecule. Insulin is a peptide; so is a junk vial sold online with no testing behind it. The word alone tells you nothing about whether something is safe, effective, legal, or worth your attention. This page is the front door to Compound Codex: a calm, skeptical orientation to what peptides are, which ones are real medicine, where the gray market starts, and how to think about the evidence for any specific one.

What a peptide actually is

A peptide is a short chain of amino acids — typically 2 to 50 — linked by chemical bonds called peptide bonds. Amino acids are the body’s basic building blocks, the same ones that make up proteins.

The line between a “peptide” and a “protein” is mostly about length, and the cutoff is somewhat arbitrary. A common convention is that chains of roughly 2 to 50 amino acids are peptides, and longer chains are proteins. You will also see narrower terms: a dipeptide has two amino acids, a tripeptide three, an oligopeptide a few, and a polypeptide many. The useful mental model is a continuum of size — amino acids build into peptides, which build into proteins — not three unrelated categories.

The takeaway is the one worth repeating: “peptide” is a description of shape and size, not a safety rating or a category of approved treatment.

How peptides work in the body

Many peptides act as hormones or signaling molecules. Because peptide hormones are water-loving and generally too large or too charged to cross a cell’s outer membrane, they usually work as “first messengers”: they bind to receptors on the surface of a cell rather than entering it.

That binding sets off chemical cascades inside the cell, often through G-protein-coupled receptors and so-called second messengers (molecules such as cAMP, cGMP, calcium, and others). The practical consequence is that peptide-hormone effects tend to be fast-acting but short-lived. This is different from steroid hormones, which are fat-soluble, slip across the membrane, and act more slowly on gene activity.

The practical lesson: peptides mostly behave like keys cut for specific locks. That specificity is exactly why a claim that one peptide “heals everything” should make you skeptical. A molecule built to fit a narrow set of receptors does not plausibly fix every unrelated problem at once.

The proven side: FDA-approved peptide drugs

There is a legitimate, heavily studied side to this field, and it is worth understanding because it is the credibility the rest of the market borrows from.

Insulin was the first peptide hormone used as medicine. The first patient, Leonard Thompson, was treated in January 1922; an initial dose triggered an allergic reaction, and a refined second dose worked. The discovery earned a Nobel Prize in 1923. Decades later, Humulin — the first biosynthetic human insulin made with recombinant DNA technology — was FDA-approved in October 1982, and it was the first approved medical product of any kind made that way.

Since then, more than 80 peptide drugs have been approved by the FDA. (You may see larger global figures in the range of 120 to 140; treat those as approximate secondary estimates rather than a firm count.) The first FDA-approved peptide anticancer drug, goserelin, was approved in late 1989 for advanced prostate cancer.

The most familiar modern peptide drugs are the GLP-1 receptor agonists, the largest current class:

Semaglutide — sold as Ozempic and Rybelsus for type 2 diabetes and Wegovy for chronic weight management.
Tirzepatide — a dual GIP/GLP-1 agonist sold as Mounjaro for type 2 diabetes and Zepbound for weight management.
Others include liraglutide, dulaglutide, exenatide, and lixisenatide.

What “peptide drug” means when it is done right: years of clinical trials, manufacturing standards, a prescription, and a known risk profile. That is a very different thing from a vial bought online.

The gray market: “research use only” peptides

A large number of peptides discussed online are not approved drugs and are not dietary supplements. They are sold under the label “Research Use Only” (RUO), often with phrases like “not for human consumption.”

RUO is a real regulatory category — for laboratory products that have not been validated or approved for use in people. The standard label reads “For Research Use Only. Not for use in diagnostic procedures.” But here is the part that matters: under FDA guidance, RUO status is determined by a product’s actual intended use, not by what a vendor prints on a label. A seller cannot escape drug regulation simply by stamping “research use only” on a product that is plainly being marketed for people to inject.

In practice, that disclaimer functions as a liability shield. It lets online vendors sell unapproved compounds — names you will see include BPC-157, TB-500, and various growth-hormone-releasing peptides — to customers who inject them anyway, with no pharmaceutical oversight, no enforced quality control, no standardized preparation, and no physician involved. Reporting on the space has documented unknown purity and contents, risks of immune reactions and impurities, and an absence of human safety and efficacy data; some unregulated products have been found to contain contaminants such as arsenic and lead.

The honest reading of “research use only” is this: it is doing legal work, not safety work. It means the seller is explicitly not claiming the product is safe for you. We go deeper on this in The Gray Market and Research Use Only, Explained.

The regulatory picture is in flux

This area is changing, so it is worth stating carefully and dating each fact.

In September 2023, the FDA placed a group of peptides into “Category 2” of its interim list of bulk drug substances for compounding under section 503A — flagging them as having significant safety concerns that made them unsuitable for bulk compounding, citing issues like immune reactions, impurities, and limited human clinical data.

On the GLP-1 front, the FDA declared the semaglutide shortage resolved in February 2025. The temporary enforcement-discretion periods that had allowed compounding ended for 503A pharmacies in April 2025 and for 503B outsourcing facilities in May 2025; the tirzepatide discretion period also ended in 2025.

More recently — and this part is still developing — HHS Secretary Robert F. Kennedy Jr. said on a February 27, 2026 podcast appearance that he is “a big fan” of peptides and claimed the FDA had “illegally reclassified 19 peptides” under the prior administration. That is his political characterization, not an established legal finding, and it should be read as a quote, not a fact. Subsequently, on April 15, 2026, the FDA removed seven peptides from Category 2 and scheduled them for review by the Pharmacy Compounding Advisory Committee (PCAC): a July 23–24, 2026 meeting (covering BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, and Epitalon), with a second set scheduled for review before the end of February 2027.

Two clarifications are essential to avoid being misled. First, as of this writing (June 2026), the July meeting has not happened and no outcome exists — anyone predicting a result is guessing. Second, PCAC is advisory only. It recommends; the FDA would still need to go through formal rulemaking to add anything to the 503A list. And even a listing would, at most, let compounding pharmacies dispense these with a prescription. It would not be a general FDA approval of those peptides as safe and effective drugs. Several of these compounds have their own Ledger entries — see BPC-157, for example — where we track this individually.

The sports and anti-doping angle

Peptide hormones, growth factors, related substances, and their mimetics fall under category S2 of the World Anti-Doping Agency (WADA) Prohibited List, banned at all times — both in and out of competition.

Banned examples include growth-hormone secretagogues (such as MK-677, ipamorelin, the GHRP series, hexarelin, and CJC-1295) and TB-500 / thymosin beta-4. The point for a newcomer is simple: many of the “wellness” peptides marketed casually online are literally on the world anti-doping banned list. That is a strong signal these are biologically active agents, not benign supplements. We cover this in Peptides and Anti-Doping.

Why the space is so hyped

The current wave is largely social-media-driven. Influencers reframed injectable peptides as “biohacking” for longevity, skin, sleep, healing, libido, and weight loss. By reported figures, the peptide hashtag has appeared on over 270,000 TikTok videos and over 654,000 Instagram posts, and U.S. peptide-related searches reportedly hit roughly 10 million in a single month in early 2026 (a large share of that GLP-1-related).

Two forces drive the hype. One is a genuine “halo effect”: Ozempic, Wegovy, and Zepbound actually work and are FDA-approved, which made “peptide” a mainstream word and lent borrowed credibility to unrelated, unapproved compounds. The other is the perennial appeal of a simple fix, amplified by e-commerce and recommendation algorithms. Neither force tells you anything about whether a specific gray-market peptide is safe or effective.

How to weigh the evidence

When you read a claim about any specific peptide, place the evidence on a hierarchy. From strongest to weakest, it runs roughly: systematic reviews and meta-analyses, then randomized controlled trials (RCTs), then cohort studies, case-control studies, case series and reports, then animal studies, and finally test-tube (in vitro) work. RCTs rank high because randomization balances out both known and unknown confounding factors. Animal and lab studies are useful for generating hypotheses, but they are not proof of benefit in humans.

A worked example makes this concrete. Most published research on BPC-157 traces back to a single research group, is overwhelmingly done in rodents, and includes almost no human trial evidence. The lead researcher holds patents and commercial interests that were not disclosed in the published papers, and the 2023 FDA action flagged potential safety risks. One formal literature review concluded the substance should not be used by humans without better human research. Plenty of citations exist — but they sit at the bottom of the evidence pyramid, which is very different from “proven in people.” Our How to Read a Peptide Study guide expands on this.

A short checklist for any peptide you encounter:

Is it FDA-approved for a specific use, or sold “for research use only”?
Where does the evidence sit — human RCTs, or rodents and anecdotes?
Is the evidence independent and replicated, or from a single group or unpublished?
Is it on the WADA banned list?
Are you being pulled in by the GLP-1 halo? Approved drugs working does not transfer to an unrelated vial.

Bottom line

“Peptide” is a description of a molecule’s structure, not a category of safe or proven treatment. On one end sit decades of rigorous, FDA-approved medicine like insulin and the GLP-1 drugs. On the other sits a fast-growing gray market that borrows that credibility while selling unapproved compounds under a “research use only” label that does legal work, not safety work. The regulatory picture is genuinely in motion in 2026, but advisory reviews and political statements are not the same as approval. The reliable move is to ignore the word “peptide” as a signal of quality and instead ask, every time, where the actual human evidence stands for the specific compound in front of you. Use the Ledger for compound-by-compound evidence grades, and our guides on how to read a study, reading a certificate of analysis, and reconstitution and handling to go deeper.